CPhI Worldwide and CPhI Pharma Evolution, part of UBM Live's Pharmaceutical Portfolio, announce the release of the first section of its annual report -- with forward looking article submissions from According to a release, the outlook for the next few years is particularly optimistic for the ADCs market where
"In the past a major failing with ADCs has been that cytotoxic agents were simply not active enough to kill the target cell with such a small amount of payload -- 0.01 percent -- however, new technologies that improve antibody and antigen conjugation could hold the key to really unlocking their potential. Over the next 10 years we will see ADCs with much higher penetration rates." --
Fujifilm Diosynth Biotechnologies Senior Vice President of R&D and Innovation,
The solution to this problem is health based approaches, so that even when there is only partial data on early phase development work and the likely doses they will be used at to support full PDE and MACO (Maximum allowable carryover) values there is still sufficient information to produce appropriate banding to evaluate risk. The cost reductions and increase in new technology will help accelerate the development of new biologics product classes and it's now up to the regulators to implement these changes into the way assessments are conducted that maintain safety without compromising development.
CPhI and Pharma Evolution will release its remaining annual report findings (10 further expert submissions) at CPhI 2013 (Frankfurt Messe 22-24th October), with a closed session press conference on the reports taking place on the first day of the event.
Chris Kilbee -- Group Director, CPhI & Pharma, confirmed the intention to distribute the full findings at this year's event: "At CPhI we will be releasing the remaining 10 articles from our panel members, which collectively will produce an in-depth overview of the market and will enable the industry to take stock and look at the implications over the next few years. We have designed these to be open access and to increase discussion amongst the industry, so I would encourage people to read the full submissions to get a fuller picture of our experts' perspectives. I must also take this opportunity to thank our panel for taking the time to provide their perspectives within this report."
For full copies of the submissions and overall reports please visit: http://downloads.deusm.com/pharmaevolution/CPhI-Annual- Industry-report-part-I.pdf
Earlier this year, CPhI launched a new initiative with the introduction of its annual report published in cooperation with Pharma Evolution -- written by a panel of world-leading experts across the pharmaceutical supply chain.
The vision was to harness the power of CPhI's independent position within the industry so that it could produce unbiased analysis of the global pharmaceutical industry and help bring different perspectives together.
The annual report utilises in-depth essays, looking at future contingencies. Experts were given carte blanche to evaluate current industry practices and examine the future implications for the industry.
CPhI drives growth at every step of the global pharmaceutical supply chain from drug discovery to finished dosage.
CPhI Pharma Evolution launched as a global online community where professionals from across the pharmaceutical manufacturing sector can talk with their peers and share best-practices and regulatory updates across the pharmaceutical ingredient and contract manufacturing space.
UBM Live connects people and creates opportunities for companies across five continents to develop new business, meet customers, launch new products, promote their brands, and expand their market.
((Comments on this story may be sent to firstname.lastname@example.org))
CPhI Worldwide and CPhI Pharma Evolution, part of UBM Live's Pharmaceutical Portfolio, announce the release of the first section of its annual report -- with forward looking article submissions from
According to a release, the outlook for the next few years is particularly optimistic for the ADCs market where